Recommended
Recommended
More Related Content
What's hot
Similar to Sessin 2 - Assessing the randomized trials
Similar to Sessin 2 - Assessing the randomized trials (20)
More from Euro CTO Club
More from Euro CTO Club (20)
Recently uploaded
Recently uploaded (20)
Sessin 2 - Assessing the randomized trials
- 1. Univ. Prof. Dr. med. Ulf Landmesser Chairman, Department of Cardiology Chair, Center for Cardiovascular Medicine Charité Universitätsmedizin Berlin Germany Assessing the randomized trials
- 2. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser Clinical impact of CTO recanalisation ? 01 ISCHEMIA trial 02 Assessing the randomized trials
- 3. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser Brilakis ES et al., Circulation 2019; 140(5):420-433
- 4. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser Indication of CTO-PCI ? Brilakis ES, Mashayekhi K, Burke MN. Circulation. 2019; 139(14):1684-1687
- 5. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser Recent randomized clinical CTO trials DECISION-CTO EURO-CTO Design Open label RCT Open label RCT Setting Korea 19 centers Europe 26 centers Subjects SAP or ACS [74% vs 26%] SAP Recruitment (N) Target (N) Time (Yrs) 815 1284 6 407* 600/1200 3 Comparison OMT vs CTO-PCI OMT vs CTO-PCI Primary Endpoint MACCE 3yr [Death, MI, stroke, repeat revascularisation] SAQ health status 12M Death, MI 3yr Werner GS et al.; Eur Heart J. 2018; 39(26):2484-2493 Lee SW et al.; Circulation 2019;139(14):1674-1683.
- 6. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser EuroCTO trial – Clinical Outcomes Werner GS et al.; Eur Heart J. 2018 Jul 7;39(26):2484-2493
- 7. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser Clinical impact of CTO recanalisation ? 01 ISCHEMIA trial 02 Assessing the randomized trials
- 8. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser7 NEJM 2020 Apr 9;382(15):1395-1407
- 9. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser
- 10. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser ISCHEMIA Trial – Design
- 11. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser
- 12. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser Study outcomes • “The primary outcome was a composite of death from cardiovascular causes, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest” • “A key secondary outcome was death from cardiovascular causes or myocardial infarction” Maron DJ et al. N Engl J Med 2020;382:1395-407
- 13. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser
- 14. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser …but if peri-procedural MI is re-defined as above x5 URL, this early adverse outcome becomes much bigger, tilting the balance in favor of OMT alone!!
- 15. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser
- 16. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser Medical Therapies Used Post-Randomization Ischemia Main Trial Figure 3.8.1 Proportion of Participants With Beta Blocker Use by Treatment Across Visit Intent-to-Treat Population Beta-blockers Ischemia Main Trial Figure 3.20.1 Proportion of Participants With Calcium Channel Blocker Use by Treatment Across Visit Intent-to-Treat Population Ca-channel blockers Ischemia Main Trial Figure 3.22.1 Proportion of Participants With dual antiplatelet (DAPT) Use1 by Treatment Across Visit Intent-to-Treat Population 1 DAPT use is defined as the use of aspirin and another antiplatelet medication. DAPT
- 17. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser ISCHEMIA – Conclusion for Ischemic CV Events 1
- 18. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser1 NEJM 2020 Apr 9;382(15):1408-1419.
- 19. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser2 Probability of being free from angina NEJM 2020 Apr 9;382(15):1408-1419.
- 20. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser Clinical impact of CTO recanalisation ? 01 ISCHEMIA trial 02 Assessing the randomized trials
- 21. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser CBFKARDIOLOGIEThank you
- 22. HERZMEDIZIN DER ZUKUNFT Ulf Landmesser CBFKARDIOLOGIEThank you